The ALG12 antibody is a tool used to study the ALG12 gene product, which encodes an alpha-1.6-mannosyltransferase enzyme critical in N-linked glycosylation. This process involves the attachment of oligosaccharides to proteins, essential for their proper folding, stability, and function. ALG12 catalyzes the addition of a mannose residue to the growing lipid-linked oligosaccharide (LLO) precursor in the endoplasmic reticulum (ER), specifically forming the Man7GlcNAc2 intermediate. Mutations in ALG12 are linked to congenital disorders of glycosylation (CDGs), specifically ALG12-CDG (formerly CDG-Ig), characterized by developmental delays, immune dysfunction, and other systemic abnormalities. The ALG12 antibody aids in detecting and analyzing the expression, localization, and functional status of the ALG12 protein in research models (e.g., cell lines, tissues). It is utilized in techniques like Western blotting, immunofluorescence, or immunohistochemistry to investigate glycosylation defects, disease mechanisms, or ER-associated processes. Studying ALG12 also contributes to broader insights into metabolic pathways, protein quality control, and genetic disorders tied to glycosylation errors. Its role in diagnostics and experimental research underscores its importance in both clinical and molecular biology contexts.